"Gastrointestinal Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
Descriptor ID |
D005765
|
MeSH Number(s) |
D27.505.954.483
|
Concept/Terms |
Gastrointestinal Agents- Gastrointestinal Agents
- Agents, Gastrointestinal
- Gastrointestinal Drugs
- Drugs, Gastrointestinal
Gastric Agents- Gastric Agents
- Agents, Gastric
- Gastric Drugs
- Drugs, Gastric
|
Below are MeSH descriptors whose meaning is more general than "Gastrointestinal Agents".
Below are MeSH descriptors whose meaning is more specific than "Gastrointestinal Agents".
This graph shows the total number of publications written about "Gastrointestinal Agents" by people in this website by year, and whether "Gastrointestinal Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
1997 | 1 | 0 | 1 |
1998 | 1 | 1 | 2 |
1999 | 3 | 0 | 3 |
2000 | 3 | 1 | 4 |
2001 | 4 | 0 | 4 |
2002 | 4 | 2 | 6 |
2003 | 3 | 0 | 3 |
2004 | 4 | 2 | 6 |
2005 | 6 | 1 | 7 |
2006 | 3 | 3 | 6 |
2007 | 6 | 3 | 9 |
2009 | 2 | 2 | 4 |
2010 | 3 | 0 | 3 |
2011 | 6 | 0 | 6 |
2012 | 2 | 0 | 2 |
2013 | 1 | 0 | 1 |
2014 | 5 | 0 | 5 |
2015 | 2 | 2 | 4 |
2016 | 8 | 1 | 9 |
2017 | 5 | 0 | 5 |
2018 | 10 | 3 | 13 |
2019 | 5 | 0 | 5 |
2020 | 3 | 2 | 5 |
2021 | 5 | 1 | 6 |
2022 | 0 | 3 | 3 |
2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gastrointestinal Agents" by people in Profiles.
-
Pegozafermin for NASH - A Sprint to Start a Marathon. N Engl J Med. 2023 Sep 14; 389(11):1044-1046.
-
Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Adv Ther. 2023 07; 40(7):3217-3226.
-
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance. Aliment Pharmacol Ther. 2023 03; 57(5):524-539.
-
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflamm Bowel Dis. 2022 10 03; 28(10):1549-1554.
-
Association of Antisecretory Drugs with Upper Gastrointestinal Bleeding in Patients Using Oral Anticoagulants: A Systematic Review and Meta-Analysis. Am J Med. 2022 10; 135(10):1231-1243.e8.
-
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022 01; 7(1):17-27.
-
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 2022 01; 7(1):28-37.
-
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
-
Vedolizumab and Anti-Tumour Necrosis Factor a Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 07; 15(10):1694-1706.
-
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterol J. 2021 06; 9(5):552-560.